Caprelsa is a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer.
ESTEVE has entered into an agreement with Sanofi to acquire Caprelsarights in more than 50 countries, a treatment that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer.
Health Technology Insights: Allied Health Provider Launches Training to Ease Staffing Crisis
Medullary thyroid carcinoma is a type of cancer that starts in the cells in the thyroid gland that produces the hormone calcitonin. This product is a ‘protein tyrosine kinase inhibitor’ that blocks the activity of enzymes known as tyrosine kinase. Consequently, the medicine reduces the blood supply to the cancer cells, slowing down the cancer’s growth.
“Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells. The primary treatment is surgery. However, treatments like vandetanib can often slow down or even partially reverse the tumour growth. We at ESTEVE are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient’s health and lives”, confirms José María Giménez-Arnau, Chief Scientific and Medical Officer of ESTEVE.
Health Technology Insights: Ubie Secures $125Million to Expand AI and Provider Solutions in US
In April 2024, ESTEVE acquired a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology, as a step forward towards becoming a highly specialized company. This acquisition added three new medicines to its portfolio addressing endogenous Cushing’s syndrome and Adrenocortical Carcinoma.
Furthermore, last month, ESTEVE acquired a license for a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency. Building on this, the company last month, the company secured an adjuvant therapy considered the standard of care for high-grade, resectable, non-metastatic osteosarcoma in patients between 2 and 30 years of age.
“We are proud to confirm that we are increasing our highly specialized therapies portfolio. Caprelsa will help us to improve the lives of patients all around the world. This is a step forward in ESTEVE’s international journey focused on highly specialized treatments for high unmet medical needs of patients”, concludes Jacob Tolstrup, Chief Commercial Officer of ESTEVE.
Health Technology Insights: Porton and EVA Pharma Partner to Expand CAR T-Cell Therapy Access
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire